Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Endocrinol Metab Clin North Am. 2009 Mar;38(1):121-36. doi: 10.1016/j.ecl.2008.11.002.

    Managing statin myopathy.

    Source

    The Henry Low Heart Center, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA.

    Abstract

    Approximately 10% of patients treated with statins experience some form of muscle-related side effects in clinical practice. These can range from asymptomatic creatine kinase (CK) elevation, to muscle pain, weakness, and its most severe form, rhabdomyolysis. Higher risk patients for statin myopathy are those older than 80, with a small body frame, on higher statin doses, on other medications, or with other systemic diseases including hepatic or renal diseases, diabetes mellitus, or hypothyroidism. The cause of statin myopathy is presumed to be the same for its variable presentation but has not been defined. In patients with myopathic symptoms, their symptoms and CK levels determine whether statin therapy can be continued or must be stopped.

    PMID:
    19217515
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      • Managing statin myopathy.
        Managing statin myopathy.
        Endocrinol Metab Clin North Am. 2009 Mar ;38(1):121-36. doi: 10.1016/j.ecl.2008.11.002.
        PubMed

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk